343 related articles for article (PubMed ID: 30311444)
21. TRIM37 overexpression is associated with chemoresistance in hepatocellular carcinoma via activating the AKT signaling pathway.
Tan G; Xie B; Yu N; Huang J; Zhang B; Lin F; Li H
Int J Clin Oncol; 2021 Mar; 26(3):532-542. PubMed ID: 33387087
[TBL] [Abstract][Full Text] [Related]
22. BEX1 mediates sorafenib resistance in hepatocellular carcinoma by regulating AKT signaling.
Zhuang N; Gu Z; Feng J; Chai Z; Shan J; Qian C
Cell Signal; 2023 Aug; 108():110722. PubMed ID: 37209973
[TBL] [Abstract][Full Text] [Related]
23. Targeting AMP-activated kinase impacts hepatocellular cancer stem cells induced by long-term treatment with sorafenib.
Bort A; Sánchez BG; Mateos-Gómez PA; Vara-Ciruelos D; Rodríguez-Henche N; Díaz-Laviada I
Mol Oncol; 2019 May; 13(5):1311-1331. PubMed ID: 30959553
[TBL] [Abstract][Full Text] [Related]
24. Rage induces hepatocellular carcinoma proliferation and sorafenib resistance by modulating autophagy.
Li J; Wu PW; Zhou Y; Dai B; Zhang PF; Zhang YH; Liu Y; Shi XL
Cell Death Dis; 2018 Feb; 9(2):225. PubMed ID: 29445087
[TBL] [Abstract][Full Text] [Related]
25. NR0B1 augments sorafenib resistance in hepatocellular carcinoma through promoting autophagy and inhibiting apoptosis.
Tan XL; Wang Z; Liao S; Yi M; Tao D; Zhang X; Leng X; Shi J; Xie S; Yang Y; Liu YQ
Cancer Sci; 2024 Feb; 115(2):465-476. PubMed ID: 37991109
[TBL] [Abstract][Full Text] [Related]
26. FGF19/FGFR4 signaling contributes to the resistance of hepatocellular carcinoma to sorafenib.
Gao L; Wang X; Tang Y; Huang S; Hu CA; Teng Y
J Exp Clin Cancer Res; 2017 Jan; 36(1):8. PubMed ID: 28069043
[TBL] [Abstract][Full Text] [Related]
27. MiR-21 mediates sorafenib resistance of hepatocellular carcinoma cells by inhibiting autophagy via the PTEN/Akt pathway.
He C; Dong X; Zhai B; Jiang X; Dong D; Li B; Jiang H; Xu S; Sun X
Oncotarget; 2015 Oct; 6(30):28867-81. PubMed ID: 26311740
[TBL] [Abstract][Full Text] [Related]
28. Single Agent and Synergistic Activity of the "First-in-Class" Dual PI3K/BRD4 Inhibitor SF1126 with Sorafenib in Hepatocellular Carcinoma.
Singh AR; Joshi S; Burgoyne AM; Sicklick JK; Ikeda S; Kono Y; Garlich JR; Morales GA; Durden DL
Mol Cancer Ther; 2016 Nov; 15(11):2553-2562. PubMed ID: 27496136
[TBL] [Abstract][Full Text] [Related]
29. Increased effects of 2,5-dimethylcelecoxib on sensitivity of hepatocellular carcinoma cells to sorafenib via CYP3A5 expression and activation of AMPK.
Chen Y; Pan B; Qiu J; Chen Z; Wang X; Tang N
Toxicol In Vitro; 2021 Oct; 76():105226. PubMed ID: 34293431
[TBL] [Abstract][Full Text] [Related]
30. Neuroblastoma RAS Viral Oncogene Homolog (NRAS) Is a Novel Prognostic Marker and Contributes to Sorafenib Resistance in Hepatocellular Carcinoma.
Dietrich P; Gaza A; Wormser L; Fritz V; Hellerbrand C; Bosserhoff AK
Neoplasia; 2019 Mar; 21(3):257-268. PubMed ID: 30685691
[TBL] [Abstract][Full Text] [Related]
31. AMPK-mediated up-regulation of mTORC2 and MCL-1 compromises the anti-cancer effects of aspirin.
Gao M; Kong Q; Hua H; Yin Y; Wang J; Luo T; Jiang Y
Oncotarget; 2016 Mar; 7(13):16349-61. PubMed ID: 26918349
[TBL] [Abstract][Full Text] [Related]
32. DNMT3b/OCT4 expression confers sorafenib resistance and poor prognosis of hepatocellular carcinoma through IL-6/STAT3 regulation.
Lai SC; Su YT; Chi CC; Kuo YC; Lee KF; Wu YC; Lan PC; Yang MH; Chang TS; Huang YH
J Exp Clin Cancer Res; 2019 Nov; 38(1):474. PubMed ID: 31771617
[TBL] [Abstract][Full Text] [Related]
33. Fibrinogen-Like Protein 1 Modulates Sorafenib Resistance in Human Hepatocellular Carcinoma Cells.
Son Y; Shin NR; Kim SH; Park SC; Lee HJ
Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34069373
[TBL] [Abstract][Full Text] [Related]
34. Upregulated expression of Nucleostemin/GNL3 is associated with poor prognosis and Sorafenib Resistance in Hepatocellular Carcinoma.
Hua L; Hu B; Yan D; Liu J; Shen Y; Zhao F; Shen C; Chen B; Cui X
Pathol Res Pract; 2017 Jun; 213(6):688-697. PubMed ID: 28476378
[TBL] [Abstract][Full Text] [Related]
35. CRIPTO promotes an aggressive tumour phenotype and resistance to treatment in hepatocellular carcinoma.
Karkampouna S; van der Helm D; Gray PC; Chen L; Klima I; Grosjean J; Burgmans MC; Farina-Sarasqueta A; Snaar-Jagalska EB; Stroka DM; Terracciano L; van Hoek B; Schaapherder AF; Osanto S; Thalmann GN; Verspaget HW; Coenraad MJ; Kruithof-de Julio M
J Pathol; 2018 Jul; 245(3):297-310. PubMed ID: 29604056
[TBL] [Abstract][Full Text] [Related]
36. FAM9C plays an anti-apoptotic role through activation of the PI3K/Akt pathway in human hepatocellular carcinoma.
Zhou JD; Shen F; Ji JS; Zheng K; Huang M; Wu JC
Oncol Rep; 2013 Sep; 30(3):1275-84. PubMed ID: 23836295
[TBL] [Abstract][Full Text] [Related]
37. KDM5B regulates the PTEN/PI3K/Akt pathway to increase sorafenib-resistance in hepatocellular carcinoma.
Liu J; Nie C
Anticancer Drugs; 2022 Oct; 33(9):840-849. PubMed ID: 35946516
[TBL] [Abstract][Full Text] [Related]
38. Des-gamma-carboxy prothrombin antagonizes the effects of Sorafenib on human hepatocellular carcinoma through activation of the Raf/MEK/ERK and PI3K/Akt/mTOR signaling pathways.
Cui SX; Shi WN; Song ZY; Wang SQ; Yu XF; Gao ZH; Qu XJ
Oncotarget; 2016 Jun; 7(24):36767-36782. PubMed ID: 27167344
[TBL] [Abstract][Full Text] [Related]
39. Arsenic trioxide potentiates the anti-cancer activities of sorafenib against hepatocellular carcinoma by inhibiting Akt activation.
Zhai B; Jiang X; He C; Zhao D; Ma L; Xu L; Jiang H; Sun X
Tumour Biol; 2015 Apr; 36(4):2323-34. PubMed ID: 25416439
[TBL] [Abstract][Full Text] [Related]
40. Glycolysis maintains AMPK activation in sorafenib-induced Warburg effect.
Guo S; Zhang C; Zeng H; Xia Y; Weng C; Deng Y; Wang L; Wang H
Mol Metab; 2023 Nov; 77():101796. PubMed ID: 37696356
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]